



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

Ref.: ADL/SE/2016-17
Date: 12th August, 2016

To,
Department of Corporate Service,
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.
BSE CODE - 524348

To,
National Stock Exchange of India Limited,
"Exchange Plaza", Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051.
NSE SYMBOL: AARTIDRUGS

Sub: Press Release

Dear Sir/Madam,

Please find enclosed herewith copy of the press release issued by the Company on 12th August, 2016.

This is for your kind information and records. Kindly acknowledge the receipt.

Thanking you,

Yours faithfully,
For Aarti Drugs Limited

V. S. Ranade

Vibhav S. Ranade
Company Secretary & Compliance Officer

Encl: A/A





Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

Press Release

Press release for Jun'16:

Domestic market share for the key products has grown significantly over same quarter of the previous year. Due to falling crude prices, raw material and consequently the finished goods selling prices have shown a downward trend. This has led to raw material inventory loss, adversely affecting the bottom-line, but it was partially mitigated by the increased market share to the extent of 17.21% across its products.

Consolidated Profit after tax for the quarter ended Jun'16 is 19.94 crores, up by 14.64% due to strong operational performance and reduction in overall interest cost. Consolidated EBITDA for the quarter ended Jun'16 is 48.14 crores, up by 8.84%. Company was able to keep its working capital cycle to optimum and further reduced the Debt/Equity ratio.

Expanded capacities from the last year's expansion program have contributed to increased sales, which is evident in the number of units sold. Company recently replied to USFDA's request for information and is further upgrading its quality systems, with the help of USFDA consultants.

For Aarti Drugs Limited

Harshit M. Savla
Jt. Managing Director
DIN: 00005340

